THE USE OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY TO ASSESS CLINICAL OUTCOMES OF PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC CANCER

MLA

Durmus, A., et al. The Use of 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess Clinical Outcomes of Patients with Borderline Resectable Pancreatic Cancer. Apr. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......9651..50f6f600070309657509726fc196d63a&authtype=sso&custid=ns315887.

APA

Durmus, A., Yilmaz, A., Malya, F. Ü., Ozturk, G., Bektasoglu, H. K., Ertugrul, G., Karyagar, S., & Karatepe, O. (2016). The Use of 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess Clinical Outcomes of Patients with Borderline Resectable Pancreatic Cancer.

Chicago

Durmus, A, A Yilmaz, Fatma Ümi̇t Malya, G Ozturk, Hüseyi̇n Kazim Bektasoglu, G Ertugrul, S Karyagar, and O Karatepe. 2016. “The Use of 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess Clinical Outcomes of Patients with Borderline Resectable Pancreatic Cancer,” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......9651..50f6f600070309657509726fc196d63a&authtype=sso&custid=ns315887.